Explore

Rapid Read Rapid Read
Generative AI Poised to Revolutionize Cancer Drug Trials, Addressing Recruitment Failures and Costly Development

Generative AI Poised to Revolutionize Cancer Drug Trials, Addressing Recruitment Failures and Costly Development

The development of new cancer drugs is an arduous and expensive process, often exceeding a billion US dollars and taking nearly a decade, with a high rate of failure. A primary reason for these failures is recruitment issues in clinical trials, a problem exacerbated by the increasing fragmentation of cancer entities into molecularly-defined subgroups in the era of precision oncology. This leads to multiple trials competing for a shrinking pool of eligible patients. Generative artificial intelligence (AI) is emerging as a potential solution by creating synthetic data that is indistinguishable from real data. This AI can generate medical images, text from electronic health records, and tabular data, including laboratory parameters, genetics, and outcomes. Unlike digital twins, which are digital replicas of individual patients, synthetic data statistically mimics feature distributions to create new samples without being exact copies of original training data. This technology aims to address the challenges of ...
Trendline Trendline
Taysha Gene Therapies Reports Positive Clinical Trial Results for Rett Syndrome Treatment TSHA-102

Taysha Gene Therapies Reports Positive Clinical Trial Results for Rett Syndrome Treatment TSHA-102

Taysha Gene Therapies Reports Positive Clinical Trial Results for Rett Syndrome Treatment TSHA-102
Rapid Read Rapid Read
Merck and Moderna Announce Promising Melanoma Vaccine Results

Merck and Moderna Announce Promising Melanoma Vaccine Results

Merck and Moderna have reported positive results for a new mRNA vaccine designed to prevent the recurrence of melanoma. According to the two pharmaceutical companies, the vaccine has enabled individuals with high-risk melanoma to experience longer periods without cancer recurrence. This development is being recognized by oncology experts as a significant step forward in cancer treatment. The vaccine leverages mRNA technology, a platform that gained prominence with COVID-19 vaccines, to target and potentially eliminate residual cancer cells, thereby reducing the likelihood of the disease returning. This approach represents a personalized medicine strategy, where the vaccine is tailored to the specific genetic mutations of a patient's tumor.
Rapid Read Rapid Read
FDA Publishes White Paper on Digitally Derived Measures for Clinical Investigations

FDA Publishes White Paper on Digitally Derived Measures for Clinical Investigations

The U.S. Food and Drug Administration (FDA) has released a white paper titled “Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations.” This document outlines important considerations for leveraging digital health technologies (DHTs) to collect data in clinical trials. The FDA emphasizes that DHTs, particularly those enhanced by artificial intelligence, can continuously capture health information in real-time and within a person's daily life, expanding beyond traditional periodic clinic visits. This initiative aligns with the FDA’s mission to protect and advance public health by supporting innovation in medical product development. The white paper aims to guide the development and use of digitally derived measures (DDMs) as outcomes in clinical investigations, advancing one of the FDA’s priorities under Public Health Pillar 1: strengthening the use of emerging technologies.
Trendline Trendline
Merck and Moderna Announce Positive Phase 3 Trial Results for Melanoma Treatment

Merck and Moderna Announce Positive Phase 3 Trial Results for Melanoma Treatment

Merck and Moderna Announce Positive Phase 3 Trial Results for Melanoma Treatment
Rapid Read Rapid Read
Personalized mRNA Cancer Vaccine Shows Promise in Melanoma Trial

Personalized mRNA Cancer Vaccine Shows Promise in Melanoma Trial

Merck and Moderna announced that a personalized mRNA-based cancer vaccine, when combined with Merck's Keytruda, has shown significant success in a large, late-stage trial for high-risk melanoma patients. This combination regimen is the first to demonstrate the potential to extend the lifespans of melanoma patients whose cancer had been surgically removed. In Phase 3 trials, the treatment significantly reduced the risk of cancer returning or spreading. Earlier Phase 2b trials indicated a 49% reduction in melanoma recurrence and a 59% reduction in metastasization to distant organs. The vaccine works by using genetic information from a patient's individual tumor to identify and target the cancer's unique mutational fingerprint.
Trendline Trendline
Teva Pharmaceuticals' Ecopipam for Pediatric Tourette Syndrome Accepted for FDA Priority Review

Teva Pharmaceuticals' Ecopipam for Pediatric Tourette Syndrome Accepted for FDA Priority Review

Teva Pharmaceuticals' Ecopipam for Pediatric Tourette Syndrome Accepted for FDA Priority Review
Trendline Trendline
Oncolytics Biotech Receives FDA Alignment for Accelerated Approval Pathway of Pelareorep in Colorectal Cancer

Oncolytics Biotech Receives FDA Alignment for Accelerated Approval Pathway of Pelareorep in Colorectal Cancer

Oncolytics Biotech Receives FDA Alignment for Accelerated Approval Pathway of Pelareorep in Colorectal Cancer
Trendline Trendline
Biokin Pharma's Iza-bren Achieves Positive Phase 3 Results in Lung Cancer Trial, Bolstering Bristol Myers Squibb Partnership

Biokin Pharma's Iza-bren Achieves Positive Phase 3 Results in Lung Cancer Trial, Bolstering Bristol Myers Squibb Partnership

Biokin Pharma's Iza-bren Achieves Positive Phase 3 Results in Lung Cancer Trial, Bolstering Bristol Myers Squibb Partnership
Rapid Read Rapid Read
FDA Approves Casgevy, First CRISPR-Based Gene Therapy for Sickle Cell Disease

FDA Approves Casgevy, First CRISPR-Based Gene Therapy for Sickle Cell Disease

The U.S. Food and Drug Administration (FDA) granted approval to Casgevy in December 2023, marking it as the first CRISPR-based gene therapy for sickle cell disease. This groundbreaking treatment utilizes the patient's own stem cells, which are genetically modified ex vivo using CRISPR-Cas9 technology. The Casgevy mechanism targets the BCL11A gene, a molecular switch that typically suppresses fetal hemoglobin production after birth. By disrupting this gene, the therapy enables the body to resume producing fetal hemoglobin, which is effective in preventing the sickling of red blood cells characteristic of sickle cell disease. This approach aims to address the root cause of the illness rather than merely managing its symptoms, offering a potential one-time cure for eligible patients. The approval followed a comprehensive review of safety and effectiveness data from multi-center clinical trials, including rigorous assessment of the CRISPR-Cas9 gene-editing precision and validation of the manufacturing process.
Rapid Read Rapid Read
Nanoplatelets Show Promise as Targeted Drug Delivery System for Cancer Therapy

Nanoplatelets Show Promise as Targeted Drug Delivery System for Cancer Therapy

Researchers have developed a novel nanoplatelet platform that could significantly advance targeted radionuclide therapy (TRT) for cancer. TRT involves attaching radioisotopes to molecules that specifically target cancer cells. The new nanoplatelet, created through a unique assembly process, possesses a specialized layered structure that allows it to rapidly absorb and strongly bind a wide variety of radioisotopes. This innovation addresses the challenge of effectively delivering short-lived radioactive isotopes to tumor sites, which are crucial for both imaging tumors and inflicting cellular damage. The platform is versatile, accommodating numerous radioisotopes, including those previously unstudied, and offers potential for both imaging and therapeutic applications, or a dual theranostic approach.
Rapid Read Rapid Read
B. Braun Medical Inc. Recalls Excel® Lactated Ringers Injection Due to Particulate Matter

B. Braun Medical Inc. Recalls Excel® Lactated Ringers Injection Due to Particulate Matter

B. Braun Medical Inc. has initiated a voluntary North American recall of one lot of its Excel® Lactated Ringers Injection, 1000mL, distributed to hospitals and healthcare facilities. The recall is due to the presence of particulate matter in the solution, primarily identified as cellulose cotton fibers, with some particles also being cellulose wood fiber and polystyrene. The affected product, with lot number J4H077 and an expiration date of November 30, 2026, was distributed nationwide in the U.S. and to Canada between August 29, 2024, and September 30, 2024. The product is used for hydration and fluid replacement in adult, pediatric, and neonatal patients. B. Braun has not received any reports of adverse events related to this recall to date. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).